Market Overview

Oculus Innovative Sciences Issued US Patent for Treatment of Skin Ulcers with Microcyn Technology

Share:
Related OCLS
Tuesday, Wednesday's Economic Conditions And Major Market Movers: China Continues To Decline, Greece Continues Delay
Morning Market Gainers
Align Technology Q2 Earnings Beat but Fall Y/Y, Stock Down - Analyst Blog (Zacks)

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) a healthcare company that designs, produces and markets innovative, safe and effective anti-infective products and medical devices while also developing multiple drug candidates, today announced the issuance of new U.S. patent for the use of Microcyn® Technology in the treatment of skin ulcers. In this application, Microcyn Technology can be delivered to skin ulcers via washing, irrigation and soaking or through application of a wound dressing saturated in the Microcyn Technology. According to claims allowed by the patent examiner, the application of the Microcyn Technology via these methods will:

* Reduce the microbial load of an infected diabetic foot ulcer; * Decrease the recurrence rate of an infected diabetic foot ulcer; * Decrease the likelihood of dehiscence of an infected diabetic foot ulcer; * Decrease the likelihood of amputation resulting from an infected diabetic foot ulcer; * Decrease the likelihood of systemic inflammatory response syndrome from an infected diabetic foot ulcer; * Decrease the likelihood of sepsis resulting from

Posted-In: News

 

Related Articles (OCLS)

Get Benzinga's Newsletters